Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by Pandoraon Nov 19, 2021 5:57pm
284 Views
Post# 34148237

RE:Boehringer Patent Application

RE:Boehringer Patent Application
PutinKhuylo1 wrote: Kind of interesting that we are mentioned here:
United States Patent Application: 0210260090 (uspto.gov)


Select New Case Application Data Transaction History Image File Wrapper Foreign Priority Published Documents Correspondence Data Supplemental Content Assignments Display Download References
 Bibliographic Data
Application Number: 17/176,285 Correspondence Address Customer Number: 33928
Filing or 371 (c) Date: 02-16-2021 Status: Docketed New Case - Ready for Examination
Application Type: Utility Status Date: 08-22-2021
Examiner Name: CENTRAL, DOCKET Location: What is a Location? ELECTRONIC
Group Art Unit: OPAP Location Date: -
Confirmation Number: 6012 Earliest Publication No: US 2021-0260090 A1
Attorney Docket Number: 01-3372-US-1 Earliest Publication Date: 08-26-2021
Class / Subclass: 514/027 Patent Number: -
First Named Inventor: Carla KROH , Oestrich-Winkel, (DE) all Inventors Issue Date of Patent: -
First Named Applicant: Boehringer Ingelheim Vetmedica GmbH , Ingelheim am Rhein, (DE) all Applicants International Registration Number (Hague): -
Entity Status: Undiscounted International Registration Publication Date: -
AIA (First Inventor to File): Yes    

USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREAT-MENT OF CARDIAC DISEASES IN FELINES
Title of Invention:  
17/176,285 USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREAT-MENT OF CARDIAC DISEASES IN FELINES 01-3372-US-1 Printer Friendly Version
Available Documents
Mail Room Date sort by Mail Room Date What is a Document Code Document Code sort by Document Code Document Description sort by Document Description What is a Document Code Document Category sort by Document Category Page Count sort by Page Count Download the selected documents as PDF
09-10-2021 N417 EFS Acknowledgment Receipt PROSECUTION 2
09-10-2021 A.PE Preliminary Amendment PROSECUTION 1
09-10-2021 CLM Claims PROSECUTION 9
09-10-2021 REM Applicant Arguments/Remarks Made in an Amendment PROSECUTION 1
09-10-2021 WFEE Fee Worksheet (SB06)


Went through the dialogue of the patent a couple of times but could not see any reference to Sirona. Would have posted it If I could have. That does not mean it is not there. Those documents are hard to read.
<< Previous
Bullboard Posts
Next >>